StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) operating KPIs

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)

Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%

Johnson & Johnson iNVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — International sales ($M) ($M)

Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule

QuarterlyAnnual
Latest, Q4 2022
62
Period ended Jan 1, 2023
Change on a year earlier
+3.3%
60 in Q4 2021
History
25 quarters
Since Q4 2016
Sources
17
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedINVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — International sales ($M) ($M)Year on yearSource
Q4 2022Jan 1, 202362+3.3%Form 10-K (filed 2023-02-16) ↗
Q3 2022Oct 2, 202260-10.4%Form 10-Q (filed 2022-10-27) ↗
Q2 2022Jul 3, 202265+1.6%Form 10-Q (filed 2022-07-29) ↗
Q1 2022Apr 3, 202268+7.9%Form 10-Q (filed 2022-04-29) ↗
Q4 2021Jan 2, 202260+3.4%Form 10-K (filed 2023-02-16) ↗
Q3 2021Oct 3, 202167-1.5%Form 10-Q (filed 2022-10-27) ↗
Q2 2021Jul 4, 202164+36.2%Form 10-Q (filed 2022-07-29) ↗
Q1 2021Apr 4, 202163+8.6%Form 10-Q (filed 2022-04-29) ↗
Q4 2020Jan 3, 202158+11.5%Form 10-K (filed 2023-02-16) ↗
Q3 2020Sep 27, 202068+23.6%Form 10-Q (filed 2021-10-29) ↗
Q2 2020Jun 28, 202047+9.3%Form 10-Q (filed 2021-07-29) ↗
Q1 2020Mar 29, 202058+18.4%Form 10-Q (filed 2021-04-30) ↗
Q4 2019Dec 29, 201952+30.0%Form 10-K (filed 2022-02-17) ↗
Q3 2019Sep 29, 201955+37.5%Form 10-Q (filed 2020-10-23) ↗
Q2 2019Jun 30, 201943-6.5%Form 10-Q (filed 2020-07-24) ↗
Q1 2019Mar 31, 201949+11.4%Form 10-Q (filed 2019-05-01) ↗

Breakdown

What makes up invokana / invokamet (canagliflozin) [reported separately through fy2022q4] — international sales ($m)

Cite this data

StockData. (2026). Johnson & Johnson INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — International sales ($M) ($M), quarterly Q4 2016–Q4 2022 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_invokana_intl

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.